The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

allosterapharma.com

Stage

Series A | Dead

Total Raised

$16.89M

Last Raised

$14.79M

About Allostera Pharma

Developer of autoimmune therapies. The company's lead therapy is an allosteric, orally active drug inhibiting a target in the autoimmune disease field, IL23R, which is a regular of TH17 cells, a class of T cells widely accepted to be the primary mediators of autoimmune diseases. By shutting off the IL23 receptor, it is believed that most autoimmune diseases, such as psoriasis, rheumatoid arthritis, Crohn's disease, and multiple sclerosis, can be controlled.

Allostera Pharma Headquarter Location

500 Cartier Boul. Ouest Suite 135

Laval, Quebec, H7V 5B7,

Canada

(450)781-0479

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

  • Where is Allostera Pharma's headquarters?

    Allostera Pharma's headquarters is located at 500 Cartier Boul. Ouest, Laval.

  • What is Allostera Pharma's latest funding round?

    Allostera Pharma's latest funding round is Series A.

  • How much did Allostera Pharma raise?

    Allostera Pharma raised a total of $16.89M.

  • Who are the investors of Allostera Pharma?

    Investors of Allostera Pharma include Inovia Capital, Genesys Capital, Fonds Bio-Innovation and CQVB.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.